Why ZEMAIRA?

Augmentation Therapy

Alpha-1 therapy involves the intravenous infusion of purified, human-derived A₁AT.⁷

The goal of therapy is to raise the A₁AT levels above the protective threshold of 11 μM (57.2 mg/dL).⁷

Other treatment options may include:

In clinical trials, ZEMAIRA has been proven to raise and maintain levels of A₁AT for chronic augmentation and maintenance therapy.²⁰

Clinical data demonstrating the long-term effects of chronic augmentation therapy are not available.